p99145 Search Results


anti pd l1 mabs  (MedChemExpress)
94
MedChemExpress anti pd l1 mabs
Figure 5 PNCK knockdown enhances the efficacy of immune checkpoint inhibition therapy. (a) The experimental schedule for the SCC7 cell challenge in the C3H mice tumor model is as follows. Intraperitoneal injections of ICIs were administered at a dose of 200 µg per mouse on the 5th, 8th, and 11th days after tumor implantation. The experiment was terminated on the 23rd day, and the tumors were removed for subsequent analysis. If the tumor volume reached 2000 mm³ during the experiment, euthanasia was performed immediately. (b) Overall tumor growth curves in different groups of mice. Mice were intraperitoneally treated with 200 µg <t>anti-PD-L1</t> or 200 µg anti-CTLA4 on days 5, 8 and 11 after tumor inoculation. A rat IgG isotype antibody was applied as a control. Two-way ANOVA with Tukey’s multiple comparison test. Data are presented as mean values±SEM. The statistical comparisons among these groups were listed as follows: WT+IgG vs KD+IgG, p=0.0258; WT+CTLA4 vs KD+CTLA4, p=0.0994; WT+PD-L1 vs KD+PD-L1, p=0.0016; WT+CTLA4 + PD-L1 vs KD+CTLA4 + PD-L1, p=0.0412; KD+IgG vs KD+CTLA4, p=0.0016; KD+IgG vs KD+PD-L1, p=0.0177; KD+CTLA4 vs KD+CTLA4 + PD-L1, p=0.0066; KD+PD-L1 vs KD+CTLA4 + PD- L1, p<0.0001. (c) Individual tumor growth curves and percentages in different groups of mice. (d) Tumor growth curve in mice with cured tumors after subcutaneous reimplantation of HNSCC. Two-way ANOVA with Tukey’s multiple comparison test was performed. Data are presented as mean values±SD. (e) Expression levels of immune markers and cytokines in tumors of mice in different groups. Kruskal-Wallis with Dunn’s multiple comparison test are reported. ANOVA, analysis of variance; ICIs, immune checkpoint inhibitors.
Anti Pd L1 Mabs, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/p99145/Anti-Mouse+PD-L1%2FB7-H1+Antibody/pm39395840-64-33-41
Average 94 stars, based on 1 article reviews
anti pd l1 mabs - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier

Image Search Results


Figure 5 PNCK knockdown enhances the efficacy of immune checkpoint inhibition therapy. (a) The experimental schedule for the SCC7 cell challenge in the C3H mice tumor model is as follows. Intraperitoneal injections of ICIs were administered at a dose of 200 µg per mouse on the 5th, 8th, and 11th days after tumor implantation. The experiment was terminated on the 23rd day, and the tumors were removed for subsequent analysis. If the tumor volume reached 2000 mm³ during the experiment, euthanasia was performed immediately. (b) Overall tumor growth curves in different groups of mice. Mice were intraperitoneally treated with 200 µg anti-PD-L1 or 200 µg anti-CTLA4 on days 5, 8 and 11 after tumor inoculation. A rat IgG isotype antibody was applied as a control. Two-way ANOVA with Tukey’s multiple comparison test. Data are presented as mean values±SEM. The statistical comparisons among these groups were listed as follows: WT+IgG vs KD+IgG, p=0.0258; WT+CTLA4 vs KD+CTLA4, p=0.0994; WT+PD-L1 vs KD+PD-L1, p=0.0016; WT+CTLA4 + PD-L1 vs KD+CTLA4 + PD-L1, p=0.0412; KD+IgG vs KD+CTLA4, p=0.0016; KD+IgG vs KD+PD-L1, p=0.0177; KD+CTLA4 vs KD+CTLA4 + PD-L1, p=0.0066; KD+PD-L1 vs KD+CTLA4 + PD- L1, p<0.0001. (c) Individual tumor growth curves and percentages in different groups of mice. (d) Tumor growth curve in mice with cured tumors after subcutaneous reimplantation of HNSCC. Two-way ANOVA with Tukey’s multiple comparison test was performed. Data are presented as mean values±SD. (e) Expression levels of immune markers and cytokines in tumors of mice in different groups. Kruskal-Wallis with Dunn’s multiple comparison test are reported. ANOVA, analysis of variance; ICIs, immune checkpoint inhibitors.

Journal: Journal for immunotherapy of cancer

Article Title: Inhibition of PNCK inflames tumor microenvironment and sensitizes head and neck squamous cell carcinoma to immune checkpoint inhibitors.

doi: 10.1136/jitc-2024-009893

Figure Lengend Snippet: Figure 5 PNCK knockdown enhances the efficacy of immune checkpoint inhibition therapy. (a) The experimental schedule for the SCC7 cell challenge in the C3H mice tumor model is as follows. Intraperitoneal injections of ICIs were administered at a dose of 200 µg per mouse on the 5th, 8th, and 11th days after tumor implantation. The experiment was terminated on the 23rd day, and the tumors were removed for subsequent analysis. If the tumor volume reached 2000 mm³ during the experiment, euthanasia was performed immediately. (b) Overall tumor growth curves in different groups of mice. Mice were intraperitoneally treated with 200 µg anti-PD-L1 or 200 µg anti-CTLA4 on days 5, 8 and 11 after tumor inoculation. A rat IgG isotype antibody was applied as a control. Two-way ANOVA with Tukey’s multiple comparison test. Data are presented as mean values±SEM. The statistical comparisons among these groups were listed as follows: WT+IgG vs KD+IgG, p=0.0258; WT+CTLA4 vs KD+CTLA4, p=0.0994; WT+PD-L1 vs KD+PD-L1, p=0.0016; WT+CTLA4 + PD-L1 vs KD+CTLA4 + PD-L1, p=0.0412; KD+IgG vs KD+CTLA4, p=0.0016; KD+IgG vs KD+PD-L1, p=0.0177; KD+CTLA4 vs KD+CTLA4 + PD-L1, p=0.0066; KD+PD-L1 vs KD+CTLA4 + PD- L1, p<0.0001. (c) Individual tumor growth curves and percentages in different groups of mice. (d) Tumor growth curve in mice with cured tumors after subcutaneous reimplantation of HNSCC. Two-way ANOVA with Tukey’s multiple comparison test was performed. Data are presented as mean values±SD. (e) Expression levels of immune markers and cytokines in tumors of mice in different groups. Kruskal-Wallis with Dunn’s multiple comparison test are reported. ANOVA, analysis of variance; ICIs, immune checkpoint inhibitors.

Article Snippet: For ICI therapy, mice with WT or Pnck- KD SCC7 cells received intraperitoneal injections of anti- mouse CTLA4 mAbs (200 μg per mouse; BioXCell, Cat No. BE0032, clone: UC10- 4F10- 11, RRID: AB_1107598), anti- PD- L1 mAbs (200 μg per mouse; MCE, Cat No. HY- P99145, clone: 10F.9G2), or corresponding isotype control mAbs on days 5, 8, and 11.

Techniques: Knockdown, Inhibition, Tumor Implantation, Control, Comparison, Expressing